These innovative compounds represent a significant leap in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://diegozhqc787362.popup-blog.com/37910133/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide